ACCEPT allows physicians to personalize the treatment of COPD patients based on predicted exacerbation risk.

For millennia, humans have developed their desired phenotypic traits in plants/animals by giving a survival advantage to those who possessed them. What if a “survival advantage” could be given to predictive models that perform better?

Preserved ratio impaired spirometry (PRISm) is a prevalent, neglected condition whose prognosis is close to that of COPD

Objective diagnostic verification of asthma in the US could result in “potential saving of $56.48 billion over 20 years”.

Can we predict which individual in the community will develop #COPD in 10 to 20 years? We might be able to.

Instead of relying on a p-value threshold of .05 or lowering it to .005, we have to calculate how much our p-value is worth. This is the probability that a positive finding in a study is a true positive—the positive predictive value (PPV). To make this more intuitive, we created p-meter, a web app that allows users to calculate positive predictive values based on the observed p-value in a positive trial.

EPIC is the first multipurpose, open-source, outcome- and policy-focused model of COPD for Canada. EPIC is available as the R package epicR or on the cloud. See more at EPIC page on RESP.

Mesenchymal stem/stromal cell (MSC) therapy may improve healing of brain aneurysms

Can we use cell to address shortcomings of aneurysm treaments?